Literature DB >> 27981572

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.

B Moriyama1, A Owusu Obeng2,3,4, J Barbarino5, S R Penzak6, S A Henning1, S A Scott2,7, Jag Agúndez8, J R Wingard9, H L McLeod10, T E Klein5, S J Cross11,12, K E Caudle11, T J Walsh13.   

Abstract

Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 ultrarapid metabolizers have decreased trough voriconazole concentrations, delaying achievement of target blood concentrations; whereas poor metabolizers have increased trough concentrations and are at increased risk of adverse drug events. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of voriconazole for treatment based on CYP2C19 genotype (updates at https://cpicpgx.org/guidelines/ and www.pharmgkb.org).
© 2016 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27981572      PMCID： PMC5474211          DOI： 10.1002/cpt.583

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  38 in total

Review 1.  Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17.

Authors:  Alain Li-Wan-Po; Thierry Girard; Peter Farndon; Candy Cooley; James Lithgow
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

2.  Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.

Authors:  Brad Moriyama; Sameer Kadri; Stacey A Henning; Robert L Danner; Thomas J Walsh; Scott R Penzak
Journal:  Curr Fungal Infect Rep       Date:  2015-04-16

3.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.

Authors:  Sarah C Sim; Carl Risinger; Marja-Liisa Dahl; Eleni Aklillu; Magnus Christensen; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  Clin Pharmacol Ther       Date:  2006-01       Impact factor: 6.875

4.  Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.

Authors:  Gerd Mikus; Verena Schöwel; Magdalena Drzewinska; Jens Rengelshausen; Reinhard Ding; Klaus-Dieter Riedel; Jürgen Burhenne; Johanna Weiss; Torben Thomsen; Walter E Haefeli
Journal:  Clin Pharmacol Ther       Date:  2006-07-03       Impact factor: 6.875

5.  Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.

Authors:  Peter F Troke; Hans P Hockey; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

6.  PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19.

Authors:  Stuart A Scott; Katrin Sangkuhl; Alan R Shuldiner; Jean-Sébastien Hulot; Caroline F Thorn; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-02       Impact factor: 2.089

7.  Effects of the CYP2C19 genetic polymorphism on gastritis, peptic ulcer disease, peptic ulcer bleeding and gastric cancer.

Authors:  Wannapa Jainan; Ratha-Korn Vilaichone
Journal:  Asian Pac J Cancer Prev       Date:  2014

8.  Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.

Authors:  Dirk Sibbing; Werner Koch; Daniela Gebhard; Tibor Schuster; Siegmund Braun; Julia Stegherr; Tanja Morath; Albert Schömig; Nicolas von Beckerath; Adnan Kastrati
Journal:  Circulation       Date:  2010-01-18       Impact factor: 29.690

Review 9.  CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?

Authors:  Aniwaa Owusu Obeng; Eric F Egelund; Abdullah Alsultan; Charles A Peloquin; Julie A Johnson
Journal:  Pharmacotherapy       Date:  2014-02-07       Impact factor: 4.705

10.  Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.

Authors:  S A Scott; K Sangkuhl; C M Stein; J-S Hulot; J L Mega; D M Roden; T E Klein; M S Sabatine; J A Johnson; A R Shuldiner
Journal:  Clin Pharmacol Ther       Date:  2013-05-22       Impact factor: 6.875
View more
  81 in total

1.  Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults.

Authors:  Naveen Mangal; Issam S Hamadeh; Meghan J Arwood; Larisa H Cavallari; Tanay S Samant; Kenneth P Klinker; Jurgen Bulitta; Stephan Schmidt
Journal:  Clin Pharmacol Ther       Date:  2018-02-13       Impact factor: 6.875

2.  Clinical Pharmacogenomics: Applications in Nephrology.

Authors:  Solomon M Adams; Karryn R Crisamore; Philip E Empey
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-23       Impact factor: 8.237

Review 3.  Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies.

Authors:  David J Epstein; Susan K Seo; Janice M Brown; Genovefa A Papanicolaou
Journal:  J Antimicrob Chemother       Date:  2018-01-01       Impact factor: 5.790

4.  Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring.

Authors:  Pier Giorgio Cojutti; Maria Merelli; Lorenzo Allegri; Giuseppe Damante; Matteo Bassetti; Federico Pea
Journal:  Br J Clin Pharmacol       Date:  2018-11-09       Impact factor: 4.335

5.  PharmGKB summary: voriconazole pathway, pharmacokinetics.

Authors:  Julia M Barbarino; Aniwaa Owusu Obeng; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2017-05       Impact factor: 2.089

Review 6.  Pharmacogenomics in dermatology: tools for understanding gene-drug associations.

Authors:  Roxana Daneshjou; Rachel Huddart; Teri E Klein; Russ B Altman
Journal:  Semin Cutan Med Surg       Date:  2019-03-01

7.  How to Transition from Single-Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial.

Authors:  Richard J Marrero; Emily J Cicali; Meghan J Arwood; Elizabeth Eddy; David DeRemer; Brian H Ramnaraign; Karen C Daily; Dennie Jones; Kelsey J Cook; Larisa H Cavallari; Kristin Wiisanen Weitzel; Taimour Langaee; Kimberly J Newsom; Petr Starostik; Michael J Clare-Salzer; Julie A Johnson; Thomas J George; Rhonda M Cooper-DeHoff
Journal:  Clin Pharmacol Ther       Date:  2020-07-06       Impact factor: 6.875

8.  Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations.

Authors:  J Kevin Hicks; Rod E Quilitz; Rami S Komrokji; Timothy E Kubal; Jeffrey E Lancet; Yanina Pasikhova; Dahui Qin; Wonhee So; Gisela Caceres; Kerry Kelly; Yasmina S Salchert; Kevin Shahbazian; Farnoosh Abbas-Aghababazadeh; Brooke L Fridley; Ana P Velez; Howard L McLeod; John N Greene
Journal:  Clin Pharmacol Ther       Date:  2019-11-01       Impact factor: 6.875

Review 9.  PharmGKB summary: very important pharmacogene information for ABCG2.

Authors:  Alison E Fohner; Deanna J Brackman; Kathleen M Giacomini; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2017-11       Impact factor: 2.089

Review 10.  The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later.

Authors:  Mary V Relling; Teri E Klein; Roseann S Gammal; Michelle Whirl-Carrillo; James M Hoffman; Kelly E Caudle
Journal:  Clin Pharmacol Ther       Date:  2019-11-05       Impact factor: 6.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.